Skip to main content
SpringerLink
Log in
Book cover

Non-medical and illicit use of psychoactive drugs pp 1–16Cite as

Preclinical Effects of Antipsychotic Drugs

  • Chapter
  • First Online:

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 34))

Abstract

Antipsychotic drugs have been the drugs of choice for the treatment of schizophrenia ever since the introduction of chlorpromazine in the early 1950s of the last century. Since then, about 60 different antipsychotics have been introduced. Although pharmacologically these drugs show large differences, in terms of potency, duration of action and selectivity, all antipsychotics appear to reduce the positive symptoms of schizophrenia, while having little or no effect on the negative symptoms or the cognitive deficits. The only apparent exception is clozapine, which is also effective in therapy-resistant patients. On the other hand, antipsychotics induce significant side effects as well, including neurological, behavioural and metabolic side effects. In the present paper, we will discuss the preclinical pharmacology of the current antipsychotic drugs focussing both on the therapeutic and on side effects of these drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aggernaes B, Glenthoj BY, Ebdrup BH et al (2010) Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months’ treatment with quetiapine. Int J Neuropsychopharmacol 13:1383–1395

    Article  CAS  PubMed  Google Scholar 

  • Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321–329

    Article  CAS  Google Scholar 

  • Arnt J (1983) Neuroleptic inhibition of 6,7-ADTN-induced hyperactivity after injections into the nucleus accumbens. Specificity and comparison with other models. Eur J Pharmacol 90:47–55

    Article  CAS  PubMed  Google Scholar 

  • Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283:55–62

    Article  CAS  PubMed  Google Scholar 

  • Arnt J (2000) Screening models for antipsychotic drugs. In: Ellenbroek BA, Cools AR (eds) Atypical antipsychotics, edn. Birkhäuser Verlag, Basel, pp 99–119

    Google Scholar 

  • Baptista T, LaCruz A, Paez X et al (2002a) The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol 447:91–98

    Article  CAS  PubMed  Google Scholar 

  • Baptista T, LaCruz A, De Mendoza D et al (2002b) Body weight gain after administration of antipsychotic drugs. Pharmacopsychiatry 35:36

    Article  PubMed  Google Scholar 

  • Braff D, Stone C, Callaway E et al (1978) Prestimulus effects of human startle reflex in normals and schizophrenics. Psychophysiology 15:339–343

    Article  CAS  PubMed  Google Scholar 

  • Braff DL (2015) The importance of endophenotypes in schizophrenia research. Schizophr Res 163:1–8

    Article  PubMed  Google Scholar 

  • Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181–188

    Article  CAS  PubMed  Google Scholar 

  • Brutcher RE, Nader MA (2015) Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys. Psychopharmacology 232:411–420

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramin and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Article  CAS  Google Scholar 

  • Cha HJ, Lee HA, Ahn JI et al (2013) Dependence potential of quetiapine: behavioral pharmacology in rodents. Biomol Ther (Seoul) 21:307–312

    Article  CAS  Google Scholar 

  • De Fazio P, Gaetano R, Caroleo M et al (2015) Rare and very rare adverse effects of clozapine. Neuropsychiatric Dis Treat 11:1995–2003

    Article  Google Scholar 

  • Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278

    Article  PubMed  PubMed Central  Google Scholar 

  • Drago F, Contarino A, Marino R et al (1997) Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacol Res 35:17–25

    Article  CAS  PubMed  Google Scholar 

  • During S, Glenthoj BY, Andersen GS et al (2014) Effects of dopamine d2/d3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology 39:3000–3008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ellenbroek B, Cools AR (1988) The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 42:1205–1213

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1–78

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA (2012) Psychopharmacological treatment of schizophrenia: what do we have and what could we get? Neuropharmacology 62:1371–1380

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA (2015) Schizophrenia: animal models. In: Stolerman IP, Price LH (eds) Encyclopedia of psychopharmacology, edn, vol 2. Springer, Heidelberg, pp 1501–1508

    Google Scholar 

  • Ellenbroek BA, Ghiabi B (2015) Do histamine receptor 3 antagonists have a place in the therapy for schizophrenia? Curr Pharm Des 21:3760–3770

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA, Cesura AM (2015) Antipsychotics and the dopamine—serotonin connection. In: Celanire S, Poli S (eds) Topics in medicinal chemistry, vol 13. Springer, Heidelberg, pp 1–50

    Google Scholar 

  • Ellenbroek BA, Artz MT, Cools AR (1991) The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103–108

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA, Prinssen EP, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1–8

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA, Lubbers LJ, Cools AR (1996) Activity of “seroquel” (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15:406–416

    Article  CAS  PubMed  Google Scholar 

  • Ellenbroek BA, Peeters BW, Honig WM et al (1987) The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology Berl 93:343–348

    Article  CAS  PubMed  Google Scholar 

  • Ersland KM, Skrede S, Rost TH et al (2015) Antipsychotic-induced metabolic effects in the female rat: direct comparison between long-acting injections of risperidone and olanzapine. J Psychopharmacol 29:1280–1289

    Article  CAS  PubMed  Google Scholar 

  • Farde L, Wiesel FA, Halldin C et al (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Article  CAS  PubMed  Google Scholar 

  • Fusar-Poli P, Papanastasiou E, Stahl D et al (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41:892–899

    Article  PubMed  Google Scholar 

  • Geyer MA, Krebs-Thomson K, Braff DL et al (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenic patients: a decade in review. Psychopharmacology 156:117–154

    Article  CAS  PubMed  Google Scholar 

  • Goldstein JM, Litwin LC, Sutton EB et al (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249:673–680

    CAS  PubMed  Google Scholar 

  • Goudie AJ, Cooper GD, Halford JCG (2005) Antipsychotic-induced weight gain. Diabetes Obes Metab 7:478–487

    Article  CAS  PubMed  Google Scholar 

  • Graham F (1975) The more or less startling effects of weak prepulses. Psychophysiology 12:238–248

    Article  CAS  PubMed  Google Scholar 

  • Haase HJ (1954) About prevalence and interpretation of the psychomotor parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492

    CAS  PubMed  Google Scholar 

  • Haase HJ, Floru L, Knaack M (1974) Clinical importance of neuroleptic threshold and its fine motor determination by handwriting test. J Int Med Res 2:321–330

    Article  Google Scholar 

  • Hartfield AW, Moore NA, Clifton PG (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 167:115–122

    Article  CAS  PubMed  Google Scholar 

  • Ishibashi T, Horisawa T, Tokuda K et al (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171–181

    Article  CAS  PubMed  Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I: neuroleptic activity spectra for rats. Arzneimittelforschung 15:104–117

    CAS  PubMed  Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Schellekens KHL (1966) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part III: The subcutaneous and oral activity in rats and dogs of 56 neuroleptic drugs in the jumping box test. Arzneimittelforschung 16:339–346

    CAS  PubMed  Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Schellekens KHL et al (1967) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part IV: An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-induced “chewing” and “agitation” in rats. Arzneimittelforschung 17:841–854

    CAS  PubMed  Google Scholar 

  • Just MJ (2015) The influence of atypical antipsychotic drugs on sexual function. Neuropsychiatric Dis Treat 11:1655–1661

    Article  CAS  Google Scholar 

  • Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097

    Article  CAS  PubMed  Google Scholar 

  • Kegeles LS, Abi-Dargham A, Frankle WG et al (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239

    Article  CAS  PubMed  Google Scholar 

  • Kelley BM, Porter JH (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707–719

    Article  CAS  PubMed  Google Scholar 

  • Klein-Schwartz W, Schwartz EK, Anderson BD (2014) Evaluation of quetiapine abuse and misuse reported to poison centers. J Addict Med 8:195–198

    Article  PubMed  Google Scholar 

  • La Torre A, Conca A, Duffy D et al (2013) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46:201–208

    Article  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962

    Article  CAS  PubMed  Google Scholar 

  • Leysen JE (2000) Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (eds) Atypical antipsychotics. Birkhäuser Verlag, Basel, pp 57–81

    Google Scholar 

  • Mackeprang T, Kristiansen KT, Glenthoj BY (2002) Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52:863–873

    Article  CAS  PubMed  Google Scholar 

  • Madras BK (2013) History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci 22:62–78

    Article  PubMed  Google Scholar 

  • Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacol Berl 94:507–514

    Article  CAS  Google Scholar 

  • Matthysse S (1986) Animal models in psychiatric research. Prog Brain Res 65:259–270

    Article  CAS  PubMed  Google Scholar 

  • Meincke U, Morth D, Voss T et al (2004) Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis—A longitudinal study. Eur Arch Psychiatry Clin Neurosci 254:415–421

    Article  PubMed  Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390–392

    CAS  PubMed  Google Scholar 

  • Moncrieff J (2013) Magic bullets for mental disorders: the emergence of the concept of an “antipsychotic” drug. J Hist Neurosci 22:30–46

    Article  PubMed  PubMed Central  Google Scholar 

  • Montebello ME, Brett J (2016) Misuse and associated harms of quetiapine and other atypical antipsychotics. Curr Topics Behav Neurosci. doi:10.1007/7854_2015_424

    Google Scholar 

  • Nielsen EB (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115–118

    Article  CAS  PubMed  Google Scholar 

  • Niemegeers CJ, Janssen PA (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201–2216

    Article  CAS  PubMed  Google Scholar 

  • Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97–103

    Article  PubMed  Google Scholar 

  • Ogren SO, Hall H, Kohler C et al (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287–294

    Article  CAS  PubMed  Google Scholar 

  • Ogren SO, Hall H, Kohler C et al (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474

    Article  CAS  PubMed  Google Scholar 

  • Porter JH, Prus AJ (2009) Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies. Psychopharmacology 203:279–294

    Article  CAS  PubMed  Google Scholar 

  • Pouzet B, Mow T, Kreilgaard M et al (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133–140

    Article  CAS  PubMed  Google Scholar 

  • Quednow BB, Wagner M, Westheide J et al (2006) Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry 59:536–545

    Article  CAS  PubMed  Google Scholar 

  • Snoeren E, Chan J, Bovens A et al (2010) Serotonin transporter null mutation and sexual behavior in female rats: 5-HT1A receptor desensitization. J Sex Med 7:2424–2434

    Article  CAS  PubMed  Google Scholar 

  • Snoeren EMS, Veening JG, Olivier B et al (2014) Serotonin 1A receptors and sexual behavior in female rats: a review. Pharmacol Biochem Behav 121:43–52

    Article  CAS  PubMed  Google Scholar 

  • Snyder SH, Greenberg D, Yamamura J (1974) Anti-schizophrenic drugsand brain cholinergic receptors. Arch Gen Psychiatry 31:58–61

    Article  CAS  PubMed  Google Scholar 

  • Steck H (1954) Le syndrome extra-pyramidal et di-encephalique au cours des traitments au Largactil et au Serpasil. Ann Med Psychol 112:737–743

    CAS  Google Scholar 

  • Stewart J (1962) Differential responses based on the physiological consequences of pharmacological agents. Psychopharmacologia 3:132–138

    Article  CAS  PubMed  Google Scholar 

  • Thomas KV, Handley SL (1978) Modulation of dexamphetamine-induced compulsive gnawing—including the possible involvement of presynaptic alpha-adrenoreceptors. Psychopharmacology 56:61–67

    Article  CAS  PubMed  Google Scholar 

  • van der Zwaal EM, Janhunen SK, la Fleur SE et al (2014) Modelling olanzapine-induced weight gain in rats. Int J Neuropsychopharmacol 17:169–186

    Article  PubMed  Google Scholar 

  • van Rossum J (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492–494

    PubMed  Google Scholar 

  • Wadenberg MG, Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851–862

    Article  CAS  PubMed  Google Scholar 

  • Zarate JM, Boksa P, Baptista T et al (2004) Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. Psychopharmacology 171:162–172

    Article  CAS  PubMed  Google Scholar 

  • Zhang XR, Zhang ZJ, Jenkins TA et al (2011) The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat. J Sex Med 8:3345–3353

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Psychology, Victoria University of Wellington, PO Box 600, Wellington, New Zealand

    Jenny Paola Berrío Sánchez & Bart A. Ellenbroek

Authors
  1. Jenny Paola Berrío Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bart A. Ellenbroek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bart A. Ellenbroek .

Editor information

Editors and Affiliations

  1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia

    Suzanne Nielsen

  2. University of Tasmania School of Psychology, Launceston, Tasmania, Australia

    Raimondo Bruno

  3. Victoria University of Wellington School of Psychology, Wellington, New Zealand

    Susan Schenk

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sánchez, J.P.B., Ellenbroek, B.A. (2016). Preclinical Effects of Antipsychotic Drugs. In: Nielsen, S., Bruno, R., Schenk, S. (eds) Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences, vol 34. Springer, Cham. https://doi.org/10.1007/7854_2016_447

Download citation

Publish with us

Policies and ethics

Search

Navigation